Bill Baruch Likes AbbVie’s Breakout as Humira Losses Get Replaced

Bill Baruch is looking at AbbVie as a healthcare name outside of the tech trade. He pointed to 7 percent earnings growth and an expected 24 percent revenue growth ahead, with Skyrizi and Rinvoq now making up for the revenue AbbVie lost as Humira came off patent. The stock is only up about 7 percent […]

Bill Baruch’s Final Trade: Nebius Group Set to Snap Back

Bill Baruch joined CNBC’s Halftime Report for his final trade, picking Nebius Group. He calls it an AI infrastructure name with an ultra growth story that has sold off nearly half from its recent high into major support. He thinks that it snaps back quickly, though he flagged it as one of the more volatile […]

Micron’s Pop Signals Capitulation on CapEx Fears, Says Bill Baruch

Bill Baruch flagged Micron as a signal he’s been watching for a couple of weeks. After its last earnings report, memory stocks including Micron ran the following day, and he reads that move as capitulation on the market’s fear around AI CapEx spending. It’s part of a broader thesis he holds on the Mag Seven […]

This Selloff Looks Like August — Bill Baruch Stays Bullish but Wants Proof

Bill Baruch thinks the selloff got exacerbated — exploding put volume, leveraged ETF selling, and profit-taking after tech charts ran straight up to the right. He’s comparing it to August 2024’s sharp drop that became the low before the summer rally kicked in. But he’s not fully convinced yet: he needs to see healthcare and […]

Reading the Cycle — Bill Baruch Trims Amazon and Alphabet Ahead of June

Bill Baruch is taking some chips off the table in Amazon and Alphabet — and the timing is deliberate. His business cycle analysis signals cyclical highs coming in June, and with a potential pullback on the horizon, he’s trimming at the top to build cash for the second half of the year. Watch the full […]